心脏衰老中的乙化:分子机制和治疗方法
Aditi Dattatraya Hase1, Sanjay K Banerjee2
1Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam, India.
Results and problems in cell differentiation
|July 1, 2025
概括
本章探讨了心脏衰老,重点关注蛋白质乙化和Sirtuins.
科学领域:
- 心脏病学 心脏病学
- 老年学是一门学科.
- 分子生物学分子生物学
背景情况:
- 心脏衰老与心脏衰老不同,涉及特定的分子机制.
- 由Sirtuins调节的蛋白质乙化在衰老过程中对心脏功能和结构起着至关重要的作用.
- 线粒体功能障碍和能量代谢的改变有助于与年龄有关的心脏功能障碍.
研究的目的:
- 阐明心脏衰老的分子机制,特别是蛋白质乙化作用.
- 为了研究线粒体功能障碍和代谢变化的对心脏衰老的影响.
- 探索缓解心脏衰老和促进心脏再生的治疗策略.
主要方法:
- 对心脏衰老背后的分子机制的审查.
- 专注于可逆蛋白质乙化和Sirtuin活性.
- 对能量代谢,线粒体功能和心肌细胞增殖的分析.
- 检查治疗干预措施,如热量限制,HDAC抑制剂,微RNA和干细胞.
主要成果:
- 赛尔图因是心脏功能和老化结构的关键调节者.
- 在衰老的心脏中,蛋白质乙化和脱乙化动态至关重要.
- 线粒体功能障碍显著影响心脏衰老.
- 心肌细胞的增殖和再生具有治疗干预的潜力.
结论:
- 了解心脏衰老涉及剖析分子途径,如蛋白质乙化.
- 针对代谢途径和细胞再生的治疗策略可能会减缓或逆转心脏衰老.
- 通过Sirtuin介导的蛋白质乙化是针对与年龄相关的心脏功能障碍的干预措施的一个有希望的目标.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
Aging
193
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
193
Cardiomyopathy V: Interprofessional Care
40
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
40
Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41
Heart Failure Drugs: Inotropic Agents
743
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
743


